BTIG Rates Haemonetics (HAE) buy, $84 Price Target

On June 26, 2026, BTIG reiterated its buy rating for Haemonetics Corporation (NYSE:HAE), setting a price target of $84. Analyst Marie Thibault emphasized the firm's positive outlook on the company's performance. Shares of Haemonetics traded near $77.62 on Friday.

Other Institutional Activity in Haemonetics Corporation

Several institutional investors made moves in their Haemonetics holdings. BlackRock, Inc. trimmed its position by 200,975 shares, holding about 5,619,979 shares valued at $316.7 million, a 3.5% decrease. Neuberger Berman Group LLC also cut its stake by 304,758 shares, ending with 3,560,918 shares worth approximately $200.6 million, a 7.9% reduction. On the other hand, AQR Capital Management LLC increased its holdings by 193,439 shares to a total of 3,356,543 shares valued at around $185.7 million, marking a 6.1% rise. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with 2,559,316 and 2,090,389 shares, respectively.

Haemonetics Corporation Stock Down 38.1%

Shares of Haemonetics Corporation traded near $77.62 on Friday. The company has a market cap of approximately $3.53 billion and a P/E ratio of 37.86, with a forward P/E of 13.48. Its beta is 0.54, indicating lower volatility compared to the market. Haemonetics' 52-week range is between $47.32 and $87.32. The stock's 50-day moving average is $64.58, while the 200-day moving average is $64.20. The company's current ratio is 2.95, and its quick ratio stands at 1.64, with a debt-to-equity ratio of 160.08.

Recent Earnings

Haemonetics reported revenue of approximately $1.33 billion, reflecting a growth of 4.8%. The company achieved a net margin of 7.29% and a return on equity of 12.03%. Earnings per share were $2.05. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Haemonetics Corporation

Recent insider transactions at Haemonetics include several sales and a notable purchase. On June 5, 2026, Maryanne Maunsell, VP and Chief Accounting Officer, sold 259 shares at an average price of $71.28. Laurie Miller, SVP of Human Resources, also sold 313 shares on the same day. In May, Chief Financial Officer James Darecca purchased 29,312 shares, while Maryanne Maunsell sold 197 shares, and President & CEO Christopher Simon sold 9,681 shares at an average price of $56.29.

Analysts Set New Price Targets

On June 26, 2026, BTIG reiterated its buy rating for Haemonetics with a price target of $84. Earlier, on June 15, Mizuho maintained its buy rating with an $85 target. B of A Securities upgraded Haemonetics to a buy with an $80 target on May 22. The consensus rating is a buy, with a mean target price of $85.20, based on 10 analyst opinions.

About Haemonetics Corporation

Haemonetics Corporation, based in Boston, Massachusetts, is a medical technology company that provides solutions for hospitals and blood centers. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers products like automated plasma collection systems and donor management software. It also provides technologies for critical care and surgery, including the TEG 6s system and the Cell Saver Elite +. Christopher A. Simon is the CEO, and the company employs about 3,009 people.

Bottom Line

BTIG's continued buy rating on Haemonetics reflects confidence in the company's growth potential. Investors often track such analyst ratings for insights into market sentiment. However, it's important to remember that these ratings are based on past performance and projections, which may not reflect future results.